Cymabay Therapeutics
CBAY
CBAY was delisted on the 21st of March, 2024.
107 hedge funds and large institutions have $627M invested in Cymabay Therapeutics in 2018 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 37 increasing their positions, 26 reducing their positions, and 8 closing their positions.
350% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 8
236% more call options, than puts
Call options by funds: $1.5M | Put options by funds: $447K
100% more capital invested
Capital invested by funds: $314M → $627M (+$313M)
42% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 26
34% more funds holding
Funds holding: 80 → 107 (+27)
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$40.5M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
+$21.1M |
| 3 |
DM
Deerfield Management
New York
|
+$15.1M |
| 4 |
Millennium Management
New York
|
+$13.6M |
| 5 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
+$12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
A
Abingworth
London,
United Kingdom
|
-$10.9M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$6.83M |
| 3 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
-$5.28M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.21M |
| 5 |
PC
Polar Capital
London,
United Kingdom
|
-$1.86M |
CBAY Hedge Fund Activity: Q1 2018 in Review
107 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q1 2018, worth a combined $627M — up 100% from $314M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new CBAY positions and 8 closed out — a net gain of 28 holders — while 37 added to existing stakes and 26 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $40.5M. The largest seller was Abingworth, cutting an estimated $10.9M.
- 107 institutional investors held Cymabay Therapeutics (CBAY) as of Q1 2018, up from 80 in Q4 2017.
- Funds reported $627M of Cymabay Therapeutics stock for Q1 2018, up 100% quarter-over-quarter.
- 36 funds opened new Cymabay Therapeutics positions in Q1 2018 and 8 closed out, a net change of +28 holders.
- The largest Cymabay Therapeutics buyer in Q1 2018 was Fidelity Investments, an estimated $40.5M added.
- The largest Cymabay Therapeutics seller in Q1 2018 was Abingworth, an estimated $10.9M sold.
Based on aggregated 13F filings for Q1 2018.